Physician profile
Mansha Sethi
NPI 1982051942
$7,630.76
in general payments reported to CMS, 2019-2025
29 companies · $81.06 in 2025
The $81.06 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,442 · 2020: $216 · 2021: $882 · 2022: $3,409 · 2023: $1,504 · 2024: $97.05 · 2025: $81.06.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,682.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,681.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,344.31 | 2019-2025 | Rinvoq, Skyrizi |
| Novartis Pharmaceuticals Corporation | $1,164.03 | 2019-2023 | |
| Regeneron Healthcare Solutions, INC. | $673.74 | 2019-2023 | Dupixent |
| Genzyme Corporation | $662.14 | 2019-2024 | |
| Janssen Biotech, INC. | $560.85 | 2019-2023 | Stelara, Simponi Aria, Simponi |
| Galderma Laboratories, L.P. | $513.82 | 2019-2023 | Epsolay, Aklief, Oracea |
| Lilly USA, LLC | $394.48 | 2021-2023 | Taltz, Olumiant |
| E.R. Squibb & Sons, L.L.C. | $310.95 | 2022-2023 | Sotyktu |
| Incyte Corporation | $255.97 | 2022-2023 | Opzelura |
| Pfizer INC. | $247.43 | 2021-2023 | |
| Sun Pharmaceutical Industries INC. | $219.56 | 2021-2023 | Absorica Ld, Winlevi |
| Amgen INC. | $156.07 | 2021-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $145.85 | 2019-2022 | |
| Allergan, INC. | $137.36 | 2019-2022 | |
| Janssen Scientific Affairs, LLC | $122.19 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $113.30 | 2022-2023 | Vtama |
| Sanofi-Aventis U.S. LLC | $99.00 | 2022 | |
| Hill Dermaceuticals, INC. | $95.50 | 2023 | Tolak |
| Arcutis Biotherapeutics, INC. | $67.48 | 2023 | |
| Ucb, INC. | $60.29 | 2022 | |
| Journey Medical Corporation | $57.57 | 2022-2023 | |
| Almirall LLC | $52.75 | 2022-2023 | Seysara |
| Epi Health, LLC | $35.22 | 2022 | |
| Revance Therapeutics, INC. | $32.56 | 2024 | Daxxify |
| Vyne Pharmaceuticals INC. | $30.87 | 2021 | |
| Leo Pharma INC. | $26.00 | 2021-2023 | Adbry |
| Biofrontera INC. | $19.20 | 2021 | |
| Regeneron Pharmaceuticals, INC. | $17.60 | 2020 | |
| Merz North America, INC. | $14.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mansha Sethi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.